Success story
Enantiopure biosynthesis of key chiral intermediate
Customer challenge
Chemical process incurred a high cost to access enantiopure quantities of a key chiral intermediate required for an oral anti-epileptic pharmaceutical.
Ingenza’s inGenius® solution
Efficient chemo-enzymatic conversion of a low-cost starting material to the desired enantiopure product, providing material to customer and cost-effective manufacturing process.
100%
100% enantioselective biosynthesis of the target
10x
10x bioprocess cost reduction following optimisation
200x
200x increase in enzyme yield from recombinant P. pastoris
Delivered
Optimised bioprocess, including recombinant enzyme prepared using P. pastoris and analytical chiral method. Multi-kilo quantities of key intermediate supplied in over 99% enantiomeric excess to support final drug development.